Syndax Pharma SNDX

$9.54 -0.05 (-0.52%)

Valuation

Market cap
863,368,000
Revenue TTM
$172,350,000
Net income TTM
$-285,420,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-165.60%
Debt to equity
0.00

Trading

Volume
2,830,100
Avg volume
2,823,076
Day's range
$9.30 – $9.93
Shares out
90,028,000
Stochastic %K
7%
Beta
0.48
Analysts
Strong Buy
Price target
$35.33

Price

Company profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also dev...

Show more

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
781 419 1400
Website
https://syndax.com
Address
730 Third Avenue, 9th Floor, New York, United States

Latest news

Stocktwits

flanker30 Nov 13, 3:19 PM
$SNDX can anything positive be expected from SNDX ? frustrating to say the least..
0 replies
Georgeson Nov 12, 6:42 PM
$SNDX Fireside chat went well this morning?
0 replies
PennyPoacher Nov 12, 5:03 PM
$SNDX sooner or later this too shall rise from the ASHes…
0 replies
BiotechSwings Nov 12, 3:28 AM
nobody brings 19 abstracts to ASH by accident imo $SNDX, Dec 12 to 15 in New Orleans 14 revumenib abstracts, 7 oral, plus 5 axatilimab with long term AGAVE 201 data behind them BEAT AML final Dec 13, SAVE Dec 14, investor event that same morning closed 9.59 today, up 1.1%, just off the 9.15 low it tagged Monday Q3 revenue did 83.3 million, up 82% vs last year, and the stock is still sitting down here into its biggest data slate of the year
2 replies
PennyPoacher Nov 11, 9:16 PM
$SNDX they’re just buying and selling to themselves. Just sitting back watching the nonsense
0 replies
k18 Nov 11, 7:19 PM
$KURA vs $SNDX Kura starting to outperform its weaker rival: 1month; 3month; 6months; the market is finally starting to take notice 👊🙏❤️
0 replies
CrispDry Nov 11, 2:09 PM
$KURA only real headwind I think was JNJ. If they are bluffing with their data, I think we can climb steadily. $SNDX can drive in a different lane. Both companies can coexist
1 replies
rabbitsoup Nov 11, 4:05 AM
$SNDX $SNDX Sorry to again express my anger- but SNDX using JWCA (J. Wood Capital Advisors LLC.) (SNDXs' $250MM convertible note underwriter) was an AMATEUR-short-sighted- anti-shaeholder move. Understand the Role of Convertible Arbitrage Investors: When companies issue or exchange convertible notes with the help of advisors like JWCA - The institutional buyers/investors (JWCA clients) purchasing those notes commonly employ a convertible arbitrage strategy. This typically involves buying the convertible notes while simultaneously establishing short positions in the underlying common stock (or using derivatives) to hedge delta and market risk. FYI- When SNDX was trading at approx.$25/share in April (they easily could have issued approx. 10-12mm straight common shares around $20/share (nice discount) and avoided all these shenanigans that now permeate the stock and will continue. Just look at the dates,charts and non-stop shorting. YET CEO brags he secured DEBT financing at great terms.
2 replies